Latest research on Vinorelbine

Vinorelbine (Navelbine®) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer. [Wikipedia]

Latest findings

In both the FAS and PAS (respectively), Paclitaxel (26% and 25%), Docetaxel (17% and 18%), trastuzumab (14% and 11%), Vinorelbine (12% and 11%), and Capecitabine (9% and 11%) were the most commonly used agents in “non-standard” regimens. [source, 2016]
Among patients with non-small cell lung cancer, the most common “standard” regimens in the FAS and PAS (n=221 and n=70, respectively) were Carboplatin plus Gemcitabine (16% in both populations), Carboplatin plus Pemetrexed (11% and 6%), and Cisplatin plus Vinorelbine (6% and 13%). [source, 2016]
Cisplatin, Carboplatin, Docetaxel, Vinorelbine, Gemcitabine, Gefitinib and Erlotinib were obtained from SellekChem. [source, 2016]
Of note, synergy was suggested for the combination of trastuzumab and Vinorelbine, [6] which is popular due to its efficacy and ease of administration in conjunction with limited toxicity. [source, 2016]
Vinorelbine constitutes effective chemotherapy for metastatic breast cancer (MBC) and acts synergistically with trastuzumab in HER-2/neu positive disease. [source, 2016]
Based upon these considerations, it seemed reasonable to hypothesize that the combination of lapatinib plus Vinorelbine could also result in significant anti-tumor activity in the challenging setting of late-line treatment in patients with HER-2/neu positive MBC pretreated with trastuzumab and lapatinib. [source, 2016]
Indeed, encouraging activity of lapatinib plus Vinorelbine combination therapy has been already demonstrated in two phase II trials [13, 14] while the concept of lapatinib beyond disease progression was not investigated henceforth. [source, 2016]
Thus, the objective of this phase II trial was to assess activity and safety of lapatinib plus Vinorelbine in HER-2/neu positive patients with MBC who had progressed on previous lapatinib-based treatment. [source, 2016]
All eligible patients with MBC were pretreated with lapatinib in combination with various cytotoxic drugs excluding Vinorelbine. [source, 2016]
Vinorelbine was administered at a dose of 20 mg/m2 by intravenous infusion on days one and eight of a three-week cycle until disease progression or the necessity of discontinuation of study treatment due to unacceptable toxicity, withdrawal of consent, loss to follow up, or death. [source, 2016]